Related Experiment Video
Updated: Jul 13, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Imaging in metastatic renal cell carcinoma
Nyree Griffin1, Martin E Gore, S Aslam Sohaib
1Department of Diagnostic Imaging, Royal Marsden Hospital, 203 Fulham Rd., London SW3 6JJ, United Kingdom.
Advanced therapies for metastatic renal cell carcinoma improve progression-free survival. Imaging will be crucial for managing and monitoring treatment response in these patients.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Metastatic renal cell carcinoma (mRCC) affects a significant patient population.
- Recent systemic therapies have improved progression-free survival in mRCC patients.
Purpose of the Study:
- To evaluate the impact of new systemic therapies on imaging practices for advanced renal cell carcinoma.
- To highlight the evolving role of imaging in mRCC management.
Main Methods:
- Review of current literature on systemic therapies for mRCC.
- Analysis of imaging guidelines and practices in the context of new treatment paradigms.
Main Results:
- New therapies significantly increase progression-free survival in metastatic renal cell carcinoma.
- These advances necessitate changes in how advanced renal cell carcinoma is imaged.
Conclusions:
- Imaging is essential for the diagnosis and monitoring of treatment response in metastatic renal cell carcinoma.
- The role of imaging in managing advanced renal cell carcinoma is expanding.
Related Concept Videos
Imaging Studies IV: Magnetic Resonance Imaging
Imaging Studies VII: Vascular Imaging
Imaging Studies III: Computed Tomography
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Imaging Studies II: Ultrasonography
Imaging Studies I: Kidney, Ureter, and Bladder Studies

